ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0677

Increased incidence of sudden cardiac death in systemic sclerosis: estimate & correlates.

Jessica Fairley1, Elizabeth Paratz2, Dylan Hansen3, Susanna Proudman4, Joanne Sahhar5, Gene-Siew Ngian6, Diane Apostolopoulos6, Jennifer Walker7, Lauren Host8, Wendy Stevens1, Andre La Gerche2, Mandana Nikpour9 and Laura Ross1, 1The University of Melbourne, Melbourne, Victoria, Australia, 2St Vincent's Institute of Medical Research, Melbourne, Victoria, Australia, 3St Vincent's Hospital Melbourne, Melbourne, Victoria, Australia, 4The University of Adelaide, Adelaide, Victoria, Australia, 5Monash Health, Melbourne, Victoria, Australia, 6Monash University, Melbourne, Victoria, Australia, 7Flinders University, Adelaide, Victoria, Australia, 8Fiona Stanley Hospital, Perth, Victoria, Australia, 9University of Sydney, School of Public Health, Faculty of Medicine and Health, Sydney, New South Wales, Australia; St Vincent’s Hospital Melbourne, Department of Rheumatology, Fitzroy, Victoria, Australia, Melbourne, Victoria, Australia

Meeting: ACR Convergence 2025

Keywords: Cardiovascular, Mortality, risk factors, Scleroderma

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 26, 2025

Title: (0671–0710) Systemic Sclerosis & Related Disorders – Clinical Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: The incidence of sudden cardiac death (SCD) is suspected to be increased in systemic sclerosis (SSc). However, data describing SCD incidence in SSc are sparse and confined to small cohorts. Accordingly, this study aims to estimate SCD incidence in SSc and assess the association with disease characteristics.

Methods: Individuals from the Australian Scleroderma Cohort Study with a definable SSc subtype meeting ACR/EULAR criteria were included. International Classification of Diseases (ICD)-10 code cause of death was sourced from the Australian National Death Index. Two authors adjudicated SCD events, which were considered present when an ICD-10 code cause of death for an acute cardiovascular pathology was listed (sudden cardiac death, cardiac arrest, ventricular fibrillation/flutter, acute myocardial infarction/acute ischaemic heart disease (IHD), ventricular tachycardia, cardiac tamponade, pericardial effusion, aortic or mitral valve lesion) excluding those with major pulmonary, renal or gastrointestinal primary causes of death. Between-group comparisons (SCD vs. overall cohort) were performed using Chi-squared testing or Wilcoxon rank-sum testing as appropriate, and multivariable Cox proportional hazard modelling was used to identify associations of SCD.

Results: Among 1708 SSc patients, 32 SCD events occurred (1.9%) over 10,650 person-years’ follow-up (Figure 1), equivalent to an observed incidence rate of 300 per 100,000 person-years. This rate is 3-9 times higher than published general population estimates (35-89/100,000 person-years).1,2Participants who experienced SCD were more likely to have IHD (40.6% vs. 13.8%, p < 0.001) and reduced left ventricular ejection fraction (LVEF < 50%; 18.5% vs. 5.5%, p=0.004). SSc heart involvement (18.8% vs. 9.4%, p=0.074), aortic valve pathology (12.9% vs. 5.7%, p=0.089) and pulmonary hypertension (18.8% vs. 11.3%, p=0.188) were numerically more common in those with SCD, although not meeting statistical significance. While cardiovascular risk factors including hypertension, dyslipidaemia and smoking history were not associated with SCD, these patients were numerically more likely to have two or more of these factors (60.7% vs. 47.5%, p=0.165). Multivariable Cox hazard modelling identified that older age (hazard ratio (HR) 1.15 (95% confidence interval (CI) 1.10-1.20), p < 0.001), IHD (HR 2.28 (95%CI 1.04-5.00), p=0.040), reduced LVEF (HR 2.89 (95%CI 1.06-7.90), p=0.038) and smoking exposure (HR 2.80 (95%CI 1.21-6.49), p=0.016) were associated with SCD.

Conclusion: SCD occurred in 1.9% of a large SSc cohort, with an incidence rate of 300 per 100,000 person-years. This is significantly higher than the rate of SCD reported in the general population. Older age, IHD, reduced LVEF and smoking were key risk factors for SCD, highlighting important and potentially modifiable risk factors for SCD in SSc. References1. Wong CX, Brown A, Lau DH, et al. Epidemiology of Sudden Cardiac Death: Global and Regional Perspectives. Heart Lung Circ 2019; 28(1): 6-14.2. Empana JP, Lerner I, Valentin E, et al. Incidence of Sudden Cardiac Death in the European Union. J Am Coll Cardiol 2022; 79(18): 1818-27

Supporting image 1Figure 1: Graphical Abstract


Disclosures: J. Fairley: Boehringer-Ingelheim, 6, Pfizer, 12, Support for ACR Registration 2021; E. Paratz: Bristol-Myers Squibb(BMS), 6, Pfizer, 12, Conference Sponsorship; D. Hansen: None; S. Proudman: Boehringer-Ingelheim, 6, Janssen, 6; J. Sahhar: Boehringer-Ingelheim, 6; G. Ngian: None; D. Apostolopoulos: None; J. Walker: Boehringer-Ingelheim, 6; L. Host: Abbvie, 6, Janssen, 6, The Limbic Publication, 6; W. Stevens: Boehringer-Ingelheim, 2, GlaxoSmithKlein(GSK), 2, Janssen, 2, Merck/MSD, 2; A. La Gerche: None; M. Nikpour: AstraZeneca, 2, 6, Boehringer-Ingelheim, 2, 6, Bristol-Myers Squibb(BMS), 2, 6, GlaxoSmithKline (GSK), 2, 6, Johnson & Johnson, 2, 6; L. Ross: None.

To cite this abstract in AMA style:

Fairley J, Paratz E, Hansen D, Proudman S, Sahhar J, Ngian G, Apostolopoulos D, Walker J, Host L, Stevens W, La Gerche A, Nikpour M, Ross L. Increased incidence of sudden cardiac death in systemic sclerosis: estimate & correlates. [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/increased-incidence-of-sudden-cardiac-death-in-systemic-sclerosis-estimate-correlates/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/increased-incidence-of-sudden-cardiac-death-in-systemic-sclerosis-estimate-correlates/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology